Results 61 to 70 of about 8,094 (259)

Psychoses in composers

, 2013
In this article, we have described the pathographies of fifty composers who were suffering from psychotic disorders. A few of them committed suicide in younger age because of schizophrenia.
Boris Ilić, Vuksanović, Marina, Trpimir Glavina, Ilić, Boris, Danijel Buljan, Vodanović, Marijo, Glavina, Trpimir, Tomislav Breitenfeld, Marijo Vodanović, Breitenfeld, Tomislav, Buljan, Danijel, Darko Breitenfeld, Marina Vuksanović, Anto Orešković, Breitenfeld, Darko, Orešković, Anto   +15 more
core  

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

The psychoactive effects of repeated ketamine infusions and their mechanistic role in the treatment of alcohol use disorder: Secondary analysis of a randomised controlled trial

Addiction, EarlyView.
Abstract Background and aims Ketamine assisted psychotherapy is a promising new treatment for alcohol use disorder (AUD). The psychoactive effects of repeated intravenous (IV) ketamine infusions in people with AUD and their mechanistic role in treating AUD are largely unknown.
Cassie Bloy, Ananya Sarma, Bethan Marsh, Lorna Hardy, Meryem Grabski, Merve Mollaahmetoglu, Joshua Shotton, Shamhethan Bhaskaran, Anne Lingford‐Hughes, H. Val Curran, Celia Morgan, Will Lawn   +11 more
wiley   +1 more source

Associations of cannabis use, tobacco use and co‐use with brain volume: A systematic review and meta‐analysis

Addiction, EarlyView.
Abstract Background and aims Cannabis is the most widely used illicit drug worldwide and is often co‐used with tobacco, the leading cause of preventable death. Although cannabis and tobacco have distinct neurobiological actions, their associations with brain volumes are unclear.
Katherine Sawyer, Tom P. Freeman, Martine Skumlien, Esther Walton, Thomas Lancaster, Jorien L. Treur, Valentina Lorenzetti, Anna K. M. Blackwell, Chloe Burke, Richie J. Carr, Constantinos Constantinides, Maisie Cox, Sarah Dance, Shadi Daryan, Sorcha Hamilton, Tom Jenkins, Gemma M. J. Taylor   +16 more
wiley   +1 more source

A call for action: Closing the evidence gap in management of stimulant‐induced psychosis

Addiction, EarlyView.
Abstract Background Stimulant‐induced psychosis (StIP) is emerging as one of most pressing health challenges. Over the past two decades, stimulant‐related harms and psychiatric care demands have risen sharply. Individuals with StIP often present with severe agitation and high suicide risk, and up to half progress to chronic psychotic illness within two
Anne Bouthillier, Heidar Sharafi, Adam Bisaga, Didier Jutras‐Aswad   +3 more
wiley   +1 more source

High temporal resolution monitoring of illicit drug consumption across England via wastewater analysis

Addiction, EarlyView.
Abstract Aim To monitor community‐level consumption of 20 illicit drugs across urban areas of England using wastewater‐based epidemiology (WBE) surveillance at high temporal resolution. Design, setting, cases This study was conducted over a 12‐month period in 2022 sampling 24‐hour composite wastewater samples at 15 wastewater treatment plants (WWTPs ...
Helena Rapp‐Wright, Keng Tiong Ng, Derryn Grant, William Francis, Margarita White, Dimitris Evangelopoulos, Yuxing Liu, Konstantina Dimakopoulou, Sofia Zafeiratou, Dylan Wood, Chryshanthi Christy, Stav Friedman, Timothy W. Gant, Klea Katsouyanni, Leon P. Barron   +14 more
wiley   +1 more source

A Randomized, Sham‐Controlled Trial of Repetitive Transcranial Magnetic Stimulation Targeting M1 and S2 in Central Poststroke Pain: A Pilot Trial

Neuromodulation: Technology at the Neural Interface, EarlyView., 2021
Abstract Objectives Central poststroke pain (CPSP), a neuropathic pain condition, is difficult to treat. Repetitive transcranial magnetic stimulation (rTMS) targeted to the primary motor cortex (M1) can alleviate the condition, but not all patients respond. We aimed to assess a promising alternative rTMS target, the secondary somatosensory cortex (S2),
Juhani Ojala, Jukka Vanhanen, Hanna Harno, Pantelis Lioumis, Selja Vaalto, Mari A. Kaunisto, Jukka Putaala, Marko Kangasniemi, Erika Kirveskari, Jyrki P. Mäkelä, Eija Kalso   +10 more
wiley   +1 more source

The association between sleep disturbance and stimulant use: A cross‐lagged examination

Addiction, EarlyView.
Abstract Background and aims Sleep disruptions increase the risk of substance misuse. Substance use—especially stimulants—can increase acute and chronic sleep dysfunction. This study aimed to estimate the associations between sleep disturbance and stimulant use over time among participants with stimulant use disorder (StUD).
Viviana E. Horigian, Renae D. Schmidt, Daniel J. Feaster, Rui Duan, Sophia T. Gonzalez, Kathryn Hefner, Dikla Shmueli‐Blumberg, Ashley Vena, Landhing M. Moran, Chloe A. DiCamillo, Shirin Shafazand, Susan Tross, Judith Feinberg   +12 more
wiley   +1 more source

Collected papers / by the medical staff of the New Jersey State Hospital at Trenton

, 1907
Vol. 1. Cytological study of the cerebro-spinal fluid by Alzheimer's method -- Case of central neuritis -- Cardio-genetic psychoses -- Some problems in the treatment and prevention of mental diseases -- Scarlet fever as an etiological factor in the ...
Cotton, Henry A., New Jersey State Hospital (Trenton, N.J.)   +1 more
core  

Unlocking ‘stuckness’ and catalysing change: A qualitative study of clinician and service leader perspectives on psychedelic‐assisted therapy for substance use and mental health problems

Addiction, EarlyView.
Abstract Background and aims Australia recently down‐scheduled and authorised psychedelic‐assisted therapies, including psilocybin, for certain mental health conditions. Evidence is emerging for potential application in substance use disorder treatment. However, regulatory developments have outpaced implementation readiness.
Sarah J. Catchlove, Katrin Oliver, Michael Savic, Shalini Arunogiri   +3 more
wiley   +1 more source